Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft model

Einav Mayzlish-Gati, Dana Laufer, Christopher F. Grivas, Julia Shaknof, Amiram Sananes, Ariel Bier, Shani Ben-Harosh, Eduard Belausov, Michael D. Johnson, Emma Artuso, Oshrat Levi, Ola Genin, Cristina Prandi, Isam Khalaila, Mark Pines, Ronit I. Yarden, Yoram Kapulnik, Hinanit Koltai

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Strigolactones (SLs) are a novel class of plant hormones. Previously, we found that analogs of SLs induce growth arrest and apoptosis in breast cancer cell lines. These compounds also inhibited the growth of breast cancer stem cell enriched-mammospheres with increased potency. Furthermore, strigolactone analogs inhibited growth and survival of colon, lung, prostate, melanoma, osteosarcoma and leukemia cancer cell lines. To further examine the anti-cancer activity of SLs in vivo, we have examined their effects on growth and viability of MDA-MB-231 tumor xenografts model either alone or in combination with paclitaxel. We show that strigolactone act as new anti-cancer agents in inhibition of breast cancer in xenograft model. In addition we show that SLs affect the integrity of the microtubule network and therefore may inhibit the migratory phenotype of the highly invasive breast cancer cell lines that were examined.

Original languageEnglish
Pages (from-to)1682-1688
Number of pages7
JournalCancer Biology and Therapy
Volume16
Issue number11
DOIs
StatePublished - 30 Oct 2015

Keywords

  • breast cancer
  • cell motility, microtubule
  • plant hormone
  • strigolactone
  • xenograft

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft model'. Together they form a unique fingerprint.

Cite this